Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Why The Time Is Ripe To Buy These Three CV Lenders For Bumper Gains



Religare has issued a comprehensive report claiming that the worst cycle for CV/CE lenders in the last 20 years is coming to an end and that a strong cyclical upturn coupled with lower fuel and funding costs could turn FY17 into a bumper year for three CV lenders




FY17 a potential bumper year for CV/CE lenders: We believe the cyclical upturn in the CV industry has already begun and will last for another 3-4 years. Recovery in demand, asset quality and margins could be sharper for NBFCs this time around given that CV volumes were severely affected in the last 2-3 years. As the CV recovery gathers pace, we expect FY17 to be a bumper year for CV/CE (commercial vehicle/construction equipment) lenders.

Click here to download Religare’s report on CV Lenders
investments, Multibagger, Portfolio, stock picker, Top Picks   

1 Comment
  1. jacob's Gravatar jacob
    April 7, 2015 at 8:19 pm | Permalink

    why none comment for religare buys!!

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap)
    Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap) for Nov '24. The Basket has delivered return of 329% since inception (May’20) vs 162% return delivered by NIFTY Index over the same period due to thematic approach to Top Picks selection Download report
  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!